Alessia Di Costanzo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1609566/publications.pdf

Version: 2024-02-01

33	832	430874	501196
papers	citations	18 h-index	28 g-index

33	33	33	1280
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Deep Resequencing of 9 Candidate Genes Identifies a Role for ARAP1 and IGF2BP2 in Modulating Insulin Secretion Adjusted for Insulin Resistance in Obese Southern Europeans. International Journal of Molecular Sciences, 2022, 23, 1221.	4.1	4
2	Metabolic Syndrome but Not Fatty Liver-Associated Genetic Variants Correlates with Glomerular Renal Function Decline in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines, 2022, 10, 720.	3.2	5
3	Twelve Variants Polygenic Score for Lowâ€Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations. Journal of the American Heart Association, 2022, 11, e023668.	3.7	12
4	The role of lipid metabolism in shaping the expansion and the function of regulatory T cells. Clinical and Experimental Immunology, 2022, 208, 181-192.	2.6	8
5	Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. European Journal of Preventive Cardiology, 2022, 29, 832-841.	1.8	23
6	The Fibrinogen-like Domain of ANGPTL3 Facilitates Lipolysis in 3T3-L1 Cells by Activating the Intracellular Erk Pathway. Biomolecules, 2022, 12, 585.	4.0	7
7	Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Longâ€Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events. Journal of the American Heart Association, 2021, 10, e018932.	3.7	24
8	Elevated Serum Concentrations of Remnant Cholesterol Associate with Increased Carotid Intima-Media Thickness in Children and Adolescents. Journal of Pediatrics, 2021, 232, 133-139.e1.	1.8	5
9	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. Orphanet Journal of Rare Diseases, 2021, 16, 381.	2.7	12
10	The Interplay between Angiopoietin-Like Proteins and Adipose Tissue: Another Piece of the Relationship between Adiposopathy and Cardiometabolic Diseases?. International Journal of Molecular Sciences, 2021, 22, 742.	4.1	21
11	Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: Implications for clinical diagnosis. Journal of Clinical Lipidology, 2021, 15, 822-831.	1.5	7
12	Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2027-2035.	2.6	11
13	Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia. Expert Opinion on Pharmacotherapy, 2020, 21, 1675-1684.	1.8	17
14	ApoCIII: A multifaceted protein in cardiometabolic disease. Metabolism: Clinical and Experimental, 2020, 113, 154395.	3.4	22
15	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines, 2020, 8, 625.	3.2	21
16	ANGPTL3 deficiency alters the lipid profile and metabolism of cultured hepatocytes and human lipoproteins. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158679.	2.4	7
17	Autosomal recessive hypercholesterolemia: update for 2020. Current Opinion in Lipidology, 2020, 31, 56-61.	2.7	22
18	Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 2301-2308.	3.9	15

#	Article	IF	Citations
19	Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2531-2541.	2.4	39
20	Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight/Obese Children. International Journal of Molecular Sciences, 2019, 20, 4444.	4.1	32
21	Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 665-674.	2.4	29
22	Genetic and metabolic predictors of hepatic fat content in a cohort of Italian children with obesity. Pediatric Research, 2019, 85, 671-677.	2.3	27
23	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Scientific Reports, 2018, 8, 3702.	3.3	59
24	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis, 2018, 277, 413-418.	0.8	48
25	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. Data in Brief, 2018, 21, 1334-1336.	1.0	4
26	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an â€œFCS scoreâ€•. Atherosclerosis, 2018, 275, 265-272.	0.8	131
27	Analysis of Children and Adolescents with Familial Hypercholesterolemia. Journal of Pediatrics, 2017, 183, 100-107.e3.	1.8	18
28	Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency. Journal of Lipid Research, 2017, 58, 994-1001.	4.2	18
29	Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage. Atherosclerosis, 2017, 257, 232-239.	0.8	39
30	PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress. Scientific Reports, 2017, 7, 15756.	3.3	45
31	Clinical and biochemical characteristics of individuals with low cholesterol syndromes: AÂcomparison between familial hypobetalipoproteinemia and familial combined hypolipidemia. Journal of Clinical Lipidology, 2017, 11, 1234-1242.	1.5	34
32	Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism. Journal of Lipid Research, 2016, 57, 1097-1107.	4.2	48
33	Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): A reappraisal by using a resequencing approach. Atherosclerosis, 2015, 242, 618-624.	0.8	18